Serum and urinary biomarkers in covid-19 patients with or without baseline chronic kidney disease

HIGHLIGHTS

SUMMARY

    In 2020, Hirsh et_al reported a high prevalence of AKI among hospitalized patients with COVID-19 (36.6%). In non-COVID-19 patients, it is estimated that 20% of hospitalized patients deteriorate to AKI and 10% of AKI patients require renal-replacement therapy (RRT). The risk factors for AKI in COVID-19 are similar to those outside of COVID-19; the presence of underlying CKD is a particularly significant risk factor. In a series of 52 COVID-19 patients, of whom 22 developed AKI, and of which 8 required RRT, Pode Shakked et_al found . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?